olaparib

epidermal growth factor receptor ; Homo sapiens







10 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35324529 Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. 2022 Mar 23 2
2 34589994 BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. 2021 Mar 2
3 32093123 Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation. 2020 Feb 19 2
4 32936912 Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. 2020 Nov 10 1
5 33070053 Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). 2020 Dec 1
6 31382135 Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. 2019 Oct 1
7 31438892 Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer. 2019 Aug 22 1
8 30407790 Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. 2018 Nov 27 3
9 26422459 Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1. 2015 Sep 1
10 23966292 EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. 2013 Oct 15 2